To evaluate whether the presence of psychiatric conditions impacts the real-world effectiveness of eptinezumab in patients with chronic migraine (CM).

Migraine is associated with many types of comorbidities, including psychiatric-related disorders (e.g., depression and anxiety), which increases the need for a more holistic approach to migraine care.

REVIEW was an observational, multi-site (n=4), US-based study to evaluate the real-world experiences of patients with CM treated with eptinezumab. Patients were ≥18 years of age, had a diagnosis of CM, and completed ≥2 consecutive eptinezumab infusion cycles. The overall study included a retrospective chart review, a patient survey, and a semi-structured physician interview; data reported here are from the patient survey.

Of the 94 patients enrolled, most (83%, 78/94) were female, with a mean age of 49 years and mean migraine diagnosis of 15.4 years. A total of 65% (61/94) self-reported psychiatric conditions, which included anxiety (50%, 47/94), depression (48%, 45/94), bipolar disorder (3%, 3/94), and “other” (4%, 4/94). In the total patient sample, patients reported a mean of 8 “good” days/month before eptinezumab treatment, which increased to 18 following treatment. Perception of efficacy was similar regardless of the presence or absence of psychiatric conditions (i.e., increasing from 8 to 18 mean “good” days/month in both subgroups). In the total population, more than 60% of patients reported higher or much higher satisfaction with various elements of daily living after starting eptinezumab treatment, and >50% of patients reported higher or much higher confidence in their overall well-being after starting eptinezumab treatment.

This real-world, patient survey showed that the patient-reported presence of psychiatric conditions, such as depression, anxiety, and bipolar disorder, did not impact the real-world effectiveness of eptinezumab.